Calcitonin; Related Peptides Patents (Class 530/307)
  • Patent number: 9862754
    Abstract: Provided herein are peptides, that in combination with metformin, are effective for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.
    Type: Grant
    Filed: October 1, 2016
    Date of Patent: January 9, 2018
    Assignee: KeyBioscience AG
    Inventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
  • Patent number: 9193776
    Abstract: The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an ?-helix; and a C-terminal fragment of modified calcitonin gene-related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: November 24, 2015
    Inventor: Christopher J. Soares
  • Publication number: 20140329752
    Abstract: The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an oc-helix; and a C-terminal fragment of modified calcitonin gene-related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide.
    Type: Application
    Filed: January 25, 2013
    Publication date: November 6, 2014
    Inventor: Christopher J. Soares
  • Publication number: 20140249076
    Abstract: Provided herein are amylin-calcitonin peptide conjugates having enhanced duration of biological activity, and methods of use thereof. The amylin-calcitonin peptide conjugates include duration enhancing moieties, such as water soluble polymers and long chain aliphatic groups, bound to the amylin-calcitonin peptide. Methods of use are provided for treatment of an eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyperlipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis or osteoarthritis.
    Type: Application
    Filed: October 17, 2012
    Publication date: September 4, 2014
    Inventors: Manoj P. Samant, Ved Srivastava, Odile Esther Levy, Christine M. Mack, William E. Rote
  • Publication number: 20140235789
    Abstract: The present application discloses peptides and peptaibols of high purity may be obtained by solid phase peptide synthesis using as the starting resin hydroxy amino acids, hydroxy amino acid amides, hydroxy amino alcohols or small peptides containing hydroxy amino acids attached to polymers through their side chain.
    Type: Application
    Filed: February 21, 2013
    Publication date: August 21, 2014
    Applicant: Chemical & Biopharmaceutical Laboratories of Patras S.A.
    Inventor: Chemical & Biopharmaceutical Laboratories of Patras S.A.
  • Patent number: 8765675
    Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: July 1, 2014
    Assignee: Novartis AG
    Inventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
  • Patent number: 8748383
    Abstract: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: June 10, 2014
    Assignees: Novartis AG, Emisphere Technologies, Inc.
    Inventors: Shoufeng Li, Anasuya Ashok Ghosh, Simon D. Bateman, Moise Azria, Alan E. Royce
  • Patent number: 8598120
    Abstract: The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: December 3, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Christopher J. Soares, Michael R. Hanley, Diana Y. Lewis, David G. Parkes, Carolyn M. Jodka, Kathryn S. Prickett, Soumitra S. Ghosh, Christine M. Mack, Qing Lin
  • Patent number: 8513188
    Abstract: This invention relates to the use of a cyclic compound of formula (I) wherein A, B independently in each occurrence is alkane-i,j-diyl having k carbon atoms, i and independently j being less than or equal k and k being selected from 1 to 10, wherein said alkane-i,j-diyl (i) may comprise one or more double bonds; (ii) is optionally substituted; and/or (iii) comprises a cycle, wherein the total number of cycles being cyclic sugars in said compound is selected from 0 to 4 and is less than p·(n+m); X,Y independently in each occurrence is a biocompatible functional group comprising at least one oxygen atom or two sulphur atoms; n, m independently of each other are selected from 0 to 20; p is selected from 1 to 10; n+m is equal or greater than 1; and p·(n+m) is selected from 3 to 30; wherein said compound is capable of forming a complex with a protonated primary and/or protonated secondary amino group and/or a protonated guanidinium group for the manufacture of a pharmaceutical or diagnostic composition.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: August 20, 2013
    Inventor: Paolo Botti
  • Patent number: 8497347
    Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: July 30, 2013
    Assignee: UGP Therapeutics, Inc.
    Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
  • Publication number: 20130165624
    Abstract: Compounds which can include an active (drug) moiety have the general formula (I): wherein: SA is a pentapeptide aa1-aa2-aa3-aa4-aa5, wherein at least one of aa1, aa2, aa3, aa4, and aa5 is L, I, E, D, and I, respectively, wherein L, I, E, and D are eponymous amino acids; SB is a dipeptide aa6-aa7, wherein at least one of aa6 and aa7 is L and W, respectively, wherein W and L are eponymous amino acids; R1 and R5 are N-, and C-terminal moieties, respectively; R3 and R4 are independently a linker selected from a substituted or unsubstituted methylene, an amino acid, a peptide, and a peptide bond; and S is a scaffold moiety, a bond, a peptide bond, an amino acid, or a peptide of up to three residues, wherein R3, S, and R4 together form a turn in the compound, and the compound selectively binds a serum albumin.
    Type: Application
    Filed: December 22, 2012
    Publication date: June 27, 2013
    Applicant: SRI INTERNATIONAL
    Inventor: Hendrik Mario Geysen
  • Patent number: 8435946
    Abstract: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: May 7, 2013
    Assignees: Novartis AG, Emisphere Technologies, Inc.
    Inventors: Shoufeng Li, Anasuya A Ghosh, Simon D Bateman, Moise Azria, Alan E Royce
  • Patent number: 8410052
    Abstract: The invention is directed to a method of administering pharmaceutical compositions comprising peptide drugs such as a calcitonin in combination with one or more oral delivery agents, together with an amount of a liquid, and method of treatment of disorders responsive to the action of peptide drugs such as a calcitonin employing such method of administration so as to enhance the oral bioavailability of a calcitonin. The methods of the invention increase the oral absorption and systemic bioavailability of peptide drugs, such as a calcitonin.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: April 2, 2013
    Assignee: Novartis AG
    Inventor: Yatindra Joshi
  • Publication number: 20130071431
    Abstract: The invention relates to the preservation of an active agent, such as a polypeptide, by contacting the active agent with a preservation mixture including a sugar and polyethyleneimine.
    Type: Application
    Filed: November 13, 2012
    Publication date: March 21, 2013
    Applicant: Stabilitech Ltd.
    Inventor: Stabilitech Ltd.
  • Patent number: 8394767
    Abstract: The present invention is directed to methods of treating cancer and preventing cancer metastasis in a subject by administering a modulator of CGRP receptor signaling. The present invention is further directed to methods of identifying novel compounds that inhibit CGRP receptor signaling, and reagents and animal models useful for the same.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: March 12, 2013
    Assignee: University of Rochester
    Inventors: Ian M. Dickerson, Edward B. Brown
  • Publication number: 20130040884
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: March 22, 2012
    Publication date: February 14, 2013
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
  • Publication number: 20120245083
    Abstract: Acylated CGRP compounds with a linker have prolonged action and are valuable as medicaments.
    Type: Application
    Filed: October 27, 2010
    Publication date: September 27, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Anette Sams Nielsen, Thomas Kruse, Janos Tibor Kodra, Jesper F. Lau, Jacob Kofoed, Kirsten Raun, Cecilia Nilsson
  • Patent number: 8222298
    Abstract: Compounds, methods, uses, compositions, kits and packages for the treatment of imbalance between bone resorption and bone formation, based on uses of 4-phenyl-2-propionamidotetralin (4-P-PDOT) and analogs, derivatives, prodrugs, precursors thereof, and salts thereof, are described.
    Type: Grant
    Filed: November 25, 2011
    Date of Patent: July 17, 2012
    Assignee: CHU Sainte-Justine
    Inventors: Alain Moreau, Genevieve Mailhot
  • Publication number: 20120164127
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Application
    Filed: March 9, 2010
    Publication date: June 28, 2012
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey, Gregory Frost
  • Publication number: 20120142586
    Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.
    Type: Application
    Filed: November 14, 2011
    Publication date: June 7, 2012
    Applicant: Unigene Laboratories Inc.
    Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
  • Patent number: 8133505
    Abstract: The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of an agent that generates hydrophilic micro-channels, and a patch comprising a therapeutically active agent. The present invention is useful for transdermal delivery of hydrophilic agents, particularly of high molecular weight proteins.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: March 13, 2012
    Assignee: TransPharma Medical Ltd.
    Inventors: Meir Stern, Galit Levin
  • Publication number: 20120059145
    Abstract: An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an ?-helical moiety, or one or more proline residues.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 8, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventor: Elliot ALTMAN
  • Publication number: 20120045816
    Abstract: Provided herein are glycosylated polypeptide compositions with substantially reduced Neu5Gc content. The glycosylated polypeptides compositions with substantially reduced Neu5Gc content can be obtained from cell sources cultured with Neu5Gc competitor or from non-human animal sources fed a diet supplemented with Neu5Gc competitor. Also provided herein are methods of treating a human subject with said compositions.
    Type: Application
    Filed: July 14, 2011
    Publication date: February 23, 2012
    Inventors: Darius Ghaderi, Ajit Varki
  • Publication number: 20120039843
    Abstract: The present invention relates to conjugates of a polypeptide and an oligosaccharide, wherein the polypeptide is conjugated to at least one oligosaccharide-spacer residue, the oligosaccharide being a synthetic sulfated oligosaccharide comprising 4-18 monosaccharide units and per se having affinity to antithrombin III and the spacer being a bond or an essentially pharmacologically inactive flexible linking residue, or a pharmaceutically acceptable salt thereof. The conjugates of the invention have improved pharmacokinetic properties when compared to the original polypeptides (i.e. the corresponding non-conjugated polypeptides per se).
    Type: Application
    Filed: September 8, 2011
    Publication date: February 16, 2012
    Applicant: N.V. Organon
    Inventors: Ebo Sybren Bos, Martin De Kort, Meertinus Jan Smit, Constant Adriaan Anton Van Boeckel
  • Patent number: 8114958
    Abstract: The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: February 14, 2012
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Christopher J. Soares, Michael R. Hanley, Diana Y. Lewis, David Geoffrey Parkes, Carolyn M. Jodka, Kathryn S. Prickett, Soumitra S. Ghosh, Christine Marie Mack, Qing Lin
  • Publication number: 20120003712
    Abstract: The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be desirably employed in the development of long acting formulations of various peptide drugs having high in-vivo activity and markedly prolonged in-blood half-life.
    Type: Application
    Filed: March 18, 2010
    Publication date: January 5, 2012
    Applicant: HANMI HOLDINGS CO., LTD.
    Inventors: Dae Hae Song, Jae Hee Shin, Jae Min Lee, Young Kyung Park, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 8076291
    Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: December 13, 2011
    Assignee: Unigene Laboratories Inc.
    Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
  • Patent number: 8030269
    Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: October 4, 2011
    Assignee: Biocon Limited
    Inventors: Nnochiri N. Ekwuribe, Balasingam Radhakrishnan
  • Publication number: 20110236412
    Abstract: A method for preserving a polypeptide comprises (i) providing an aqueous solution of one or more sugars, a polyethyleneimine and said polypeptide wherein the concentration of polyethyleneimine is 25 ?M or less based on the number-average molar mass (Mn) of the polyethyleneimine and the sugar concentration or, if more than one sugar is present, total sugar concentration is greater than 0.1 M; and (ii) drying the solution to form an amorphous solid matrix comprising said polypeptide.
    Type: Application
    Filed: September 24, 2009
    Publication date: September 29, 2011
    Applicant: Stabilitech Ltd.
    Inventor: Jeffrey Drew
  • Publication number: 20110189205
    Abstract: The present invention is directed to methods of treating cancer and preventing cancer metastasis in a subject by administering a modulator of CGRP receptor signaling. The present invention is further directed to methods of identifying novel compounds that inhibit CGRP receptor signaling, and reagents and animal models useful for the same.
    Type: Application
    Filed: January 10, 2011
    Publication date: August 4, 2011
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Ian M. Dickerson, Edward B. Brown
  • Publication number: 20110112990
    Abstract: The present invention relates to processes for the production of peptides, and the peptides produced accordingly. Peptides produced according to the invention may be produced more efficiently than peptides produced according to prior art processes. The production process of the invention may lead to advantages in yield, purity, and/or price. Methods of marketing peptides are also disclosed.
    Type: Application
    Filed: November 9, 2010
    Publication date: May 12, 2011
    Applicants: The Regents of the University of Colorado, a body corporate, AmideBio LLC
    Inventors: Michael H. B. Stowell, Jonathan Caruthers, Travis Nemkov, Brian Hiester, Leslie Boux, Mikhail Plam
  • Publication number: 20110034385
    Abstract: The present invention provides a supramolecular protein assembly useful as a protein therapeutics for the treatment of metabolic disorders particularly diabetes. The supramolecular protein assembly disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising supramolecular protein assembly. The composition disclosed in the present invention particularly comprises supramolecular insulin assembly.
    Type: Application
    Filed: October 13, 2008
    Publication date: February 10, 2011
    Applicants: NATIONAL INSTITUTE OF IMMUNOLOGY, INDIAN INSTITUTE OF SCIENCE
    Inventors: Avadhesha Surolia, Sarika Gupta, Mahendra Singh, Tandrika Chattopadhyay
  • Publication number: 20110020273
    Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the bispecific immunocytokine DNL construct comprises an IgG antibody attached to a Fab antibody fragment and a cytokine, wherein the IgG and the Fab bind to different target antigens which may be expressed on the same target cell. The bispecific immunocytokine DNL construct exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or even other types of cytokine-antibody DNL constructs. In a most preferred embodiment the construct comprises an anti-CD20 IgG antibody conjugated to an anti-HLA-DR Fab and IFN?2b, although other combinations of antibodies, antibody fragments and cytokines may be used to form the subject DNL complexes.
    Type: Application
    Filed: August 27, 2010
    Publication date: January 27, 2011
    Applicant: IBC PHARMACEUTICALS, INC.
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Publication number: 20100311650
    Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.
    Type: Application
    Filed: January 22, 2010
    Publication date: December 9, 2010
    Applicant: UNIGENE LABORATORIES INC.
    Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
  • Patent number: 7812120
    Abstract: Compositions suitable for intranasal administration containing calcitonin, chlorobutanol, a pH of about 3.5, and sodium chloride, and an intranasal spray and a pharmaceutical delivery device thereof.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: October 12, 2010
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Steven C. Quay, Jorge C. de Meireles, Arati A. Deshpande, Zenaida O. Go, Anthony P. Sileno
  • Publication number: 20100254943
    Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.
    Type: Application
    Filed: November 2, 2009
    Publication date: October 7, 2010
    Applicant: ALLOZYNE, INC.
    Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis, Stephen McCraith, Deepshikha Datta
  • Publication number: 20100240865
    Abstract: The invention relates to methods for the preparation of polypeptides. The polypeptides are prepared in high purity of at least about 98.5%, and preferably at least about 99% by HPLC.
    Type: Application
    Filed: February 4, 2010
    Publication date: September 23, 2010
    Inventors: Avi Tovi, Chaim Eidelman, Shimon Shushan, Shai Elster, Hagi Alon
  • Publication number: 20100233783
    Abstract: Process for purifying a recombinant protein including one or a few procedural steps only. The process combines the step of lysis of the host cell, with the purification of the protein of interest, allowing for a rapid and much more efficient process of purification. The conditions used during the purification process are those of a high temperature and a low pH, allowing for thermostable and acid-resistant recombinant proteins to be isolated from a suspension. The invention also relates to purifying recombinant proteins which are fusion proteins, wherein one part of the protein may be selected from an enamel matrix protein, such as amelogenin.
    Type: Application
    Filed: March 23, 2006
    Publication date: September 16, 2010
    Applicant: Straumann Holding AG
    Inventors: Johan Per Henrik Svensson, Leif Bülow
  • Publication number: 20100227815
    Abstract: The present invention relates to site-specific PEGylated linear salmon calcitonin analogues, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.
    Type: Application
    Filed: June 4, 2008
    Publication date: September 9, 2010
    Applicant: Institute of Pharmacology and Toxicology Academy Of Military Medical Science
    Inventors: Keliang Liu, Jiankun Qie, Zhixia Yang, Yuanjun Liang, Ying Wang, Zehui Gong, Huajin Dong
  • Publication number: 20100204116
    Abstract: The present invention is directed to the use of the peptide compound Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-Nh2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
    Type: Application
    Filed: September 9, 2008
    Publication date: August 12, 2010
    Inventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
  • Patent number: 7749954
    Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: July 6, 2010
    Assignee: Novartis AG
    Inventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
  • Patent number: 7745216
    Abstract: The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: June 29, 2010
    Assignee: Curis, Inc.
    Inventors: Kevin Pang, Kuanghui Lu
  • Publication number: 20100160209
    Abstract: The invention provides for a cell permeable peptide conjugated to an insulin compound for improved cell penetration of the insulin moiety. The composition may be delivered by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means for the treatment, including prophylaxis of Type I, Type II diabetes, prediabetes and/or metabolic syndrome.
    Type: Application
    Filed: May 10, 2007
    Publication date: June 24, 2010
    Applicant: SmithKline Beecham Corporation
    Inventors: Dany Doucet, Mickey Lee Wells
  • Patent number: 7713932
    Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: May 11, 2010
    Assignee: Biocon Limited
    Inventors: Nnochiri N. Ekwuribe, Balasingam Radhakrishnan
  • Publication number: 20100105624
    Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.
    Type: Application
    Filed: October 27, 2009
    Publication date: April 29, 2010
    Inventors: Nnochiri N. Ekwuribe, Balasingam Radhakrishnan
  • Patent number: 7658917
    Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural ? amyloid peptides (?-AP). In a preferred embodiment, the ? amyloid modulator compounds of the invention are comprised of an A? aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural ? amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural ?-AP aggregation when the natural ?-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.
    Type: Grant
    Filed: June 17, 2003
    Date of Patent: February 9, 2010
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Ethan R. Signer, James Wakefield, Laura Kasman, Gary Musso, Michael J. Reed
  • Publication number: 20090286723
    Abstract: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Application
    Filed: August 11, 2006
    Publication date: November 19, 2009
    Applicant: AMYLIN PHARMACEUTICALS, INC.
    Inventors: Odile Esther Levy, Michael R. Hanley, Carolyn M. Jodka, Diana Y. Lewis, Christopher J. Soares, Soumitra S. Ghosh, Lawrence J. D'Souza, David G. Parkes, Christine M. Mack, Behrouz Bruce Forood
  • Patent number: 7608584
    Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: October 27, 2009
    Assignee: Biocon Limited
    Inventors: Nnochiri N. Ekwuribe, Balasingam Radhakrishnan
  • Patent number: 7569539
    Abstract: Disclosed is a particular method of orally administering pharmaceutical compositions comprising calcitonin in combination with oral delivery agents, prior to the consumption of food in humans, and a method of treatment of disorders responsive to the action of calcitonin employing such method of administration; also oral calcitonin pharmaceutical compositions with particular ratios of the amount of oral delivery agent to the amount of calcitonin.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: August 4, 2009
    Assignee: Novartis AG
    Inventors: Moise Azria, Simon D Bateman, James F Mcleod
  • Patent number: 7521529
    Abstract: The present invention provides a method of synthesizing an intramolecularly bridged polypeptide comprising at least one intramolecular bridge. The present invention further provides a method of synthesizing an intramolecularly bridged polypeptide comprising two intramolecular bridges, wherein the two intramolecular bridges form two overlapping ring, two rings in series, or two embedded rings. The present invention also provides methods for synthesizing lantibiotics, including Nisin A. Additionally, the invention provides intramolecularly bridged polypeptides synthesized by the methods disclosed herein and differentially protected orthogonal lanthionines.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: April 21, 2009
    Assignee: Oragenics, Inc.
    Inventors: Jeffrey D. Hillman, Ravi S. Orugunty, James L. Smith